Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Profile Name | FGFR3 - TACC3 |
| Gene Variant Detail | |
| Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR3 Inhibitor U0126 |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| FGFR3 - TACC3 | lung adenocarcinoma | sensitive | FGFR Inhibitor (Pan) | Ponatinib | Preclinical | Actionable | In a preclinical study, Iclusig (ponatanib) inhibited growth and FGFR3 phosphorylation in cells expressing FGFR3-TACC3 fusion in culture (PMID: 25294908). | 25294908 |
| FGFR3 - TACC3 | lung adenocarcinoma | sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical | Actionable | In a preclinical study, Truseltiq (infigratinib) inhibited growth and FGFR3 phosphorylation in cells expressing FGFR3-TACC3 fusion in culture (PMID: 25294908). | 25294908 |
| FGFR3 - TACC3 | high grade glioma | sensitive | FGFR3 Inhibitor | PD173074 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PD173074 inhibited Fgfr3 kinase activity and growth in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture and in cell line xenograft models (PMID: 22837387). | 22837387 |
| FGFR3 - TACC3 | high grade glioma | sensitive | FGFR3 Inhibitor | AZD4547 | Preclinical - Cell culture | Actionable | In a preclinical study, AZD4547 inhibited Fgfr3 kinase activity in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture (PMID: 22837387). | 22837387 |
| FGFR3 - TACC3 | high grade glioma | sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Truseltiq (infigratinib) inhibited Fgfr3 kinase activity in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture (PMID: 22837387). | 22837387 |
| FGFR3 - TACC3 | glioblastoma | sensitive | U0126 | U0126 | Preclinical | Actionable | In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells expressing the FGFR3-TACC3 fusion in culture (PMID: 23298836). | 23298836 |
| FGFR3 - TACC3 | transitional cell carcinoma | sensitive | FGFR Inhibitor (Pan) | Erdafitinib | Case Reports/Case Series | Actionable | In a Phase I trial, Balversa (erdafitinib) treatment resulted in partial response in 2 urothelial cancer patients harboring FGFR3-TACC3 (PMID: 26324363; NCT01703481). | 26324363 |
| FGFR3 - TACC3 | glioblastoma | predicted - sensitive | FGFR Inhibitor (Pan) | Erdafitinib | Case Reports/Case Series | Actionable | In a Phase I trial, Balversa (erdafitinib) treatment resulted in partial response in a glioblastoma patient harboring FGFR3-TACC3 fusion (PMID: 26324363; NCT01703481). | 26324363 |
| FGFR3 - TACC3 | glioblastoma | predicted - sensitive | FGFR Inhibitor (Pan) | Erdafitinib | Case Reports/Case Series | Actionable | In a clinical study, Balversa (erdafitinib) treatment resulted in tumor reduction and stable disease in 2 glioblastoma multiforme patients harboring FGFR3-TACC3 fusion (PMID: 25609060). | 25609060 |
| FGFR3 - TACC3 | high grade glioma | sensitive | FGFR Inhibitor (Pan) | Erdafitinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Balversa (erdafitinib) inhibited proliferation of glioma cells harboring FGFR3-TACC3 fusion in culture and xenograft tumor growth in animal models (PMID: 25609060). | 25609060 |
| FGFR3 - TACC3 | urinary bladder cancer | sensitive | Vofatamab | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Vofatamab (B-701) inhibited FGFR3 signaling and tumor growth in bladder cancer cell line xenograft models harboring FGFR3-TACC3 (PMID: 25326231). | 25326231 | |
| FGFR3 - TACC3 | urinary bladder cancer | no benefit | Selumetinib | Preclinical - Cell culture | Actionable | In a preclinical study, bladder cancer cells harboring FGFR3-TACC3 were not sensitive to Koselugo (selumetinib) in culture (PMID: 26438159). | 26438159 | |
| FGFR3 - TACC3 | urinary bladder cancer | sensitive | FGFR3 Inhibitor | Pazopanib | Preclinical | Actionable | In a preclinical study, bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to Votrient (pazopanib) in culture (PMID: 23558953). | 23558953 |
| FGFR3 - TACC3 | urinary bladder cancer | sensitive | FGFR Inhibitor (Pan) | LY2874455 | Preclinical | Actionable | In a preclinical study, LY2874455 induced tumor regression in bladder cancer xenograft models that have been demonstrated to harbor an FGFR3-TACC3 fusion (PMID: 21900693, PMID: 23175443). | 21900693 23175443 |
| FGFR3 - TACC3 | urinary bladder cancer | predicted - sensitive | FGFR3 Inhibitor | S-49076 | Preclinical | Actionable | In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 23804704, PMID: 23175443). | 23175443 23804704 |
| FGFR3 - TACC3 | urinary bladder cancer | sensitive | FGFR3 Inhibitor | Debio 1347 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Debio 1347 inhibited proliferation of bladder cancer cell lines harboring an FGFR3-TACC3 fusion in culture and inhibited tumor growth in FGFR3-TACC3-positive bladder cancer cell line xenograft models (PMID: 25169980). | 25169980 |
| FGFR3 - TACC3 | urinary bladder cancer | sensitive | FGFR3 Inhibitor | SU5402 | Preclinical | Actionable | In a preclinical study, SU5402 induced cell-cycle arrest and inhibited proliferation of bladder cancer cells that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 21119661, PMID: 23175443). | 21119661 23175443 |
| FGFR3 - TACC3 | urinary bladder cancer | sensitive | FGFR3 Inhibitor | AZ8010 | Preclinical | Actionable | In a preclinical study, AZ12908010 (AZ8010) induced cell cycle arrest and inhibited proliferation of urothelial cancer cell lines that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 22869148, PMID: 23175443). | 22869148 23175443 |
| FGFR3 - TACC3 | urinary bladder cancer | sensitive | FGFR Inhibitor (Pan) | Dovitinib | Preclinical | Actionable | In a preclinical study, Dovitinib (TKI258) inhibited growth of bladder cancer cell lines that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 24325461, PMID: 23175443). | 23175443 24325461 |
| FGFR3 - TACC3 | urinary bladder cancer | sensitive | FGFR Inhibitor (Pan) | FIIN-1 | Preclinical | Actionable | In a preclinical study, FIIN-1 inhibited growth of the RT4 bladder cancer cell line, which has been demonstrated to harbor an FGFR3-TACC3 fusion, in culture (PMID: 20338520, PMID: 23175443). | 23175443 20338520 |
| FGFR3 - TACC3 | urinary bladder cancer | sensitive | FGFR Inhibitor (Pan) | PRN1109 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PRN1109 treatment resulted in tumor regression in bladder cancer cell line xenograft models harboring FGFR3-TACC3 fusion (Eu J Cancer 2014 Vol 50, Suppl 6:157). | detail... |
| FGFR3 - TACC3 | urinary bladder cancer | sensitive | FGFR Inhibitor (Pan) | ASP5878 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ASP5878 treatment inhibited proliferation of bladder cancer cell lines harboring a FGFR3-TACC3 fusion in culture, and resulted in tumor regression in a FGFR3-TACC3 positive bladder cancer cell line xenograft model (Mol Cancer Ther December 2015 14; A170). | detail... |
| FGFR3 - TACC3 | transitional cell carcinoma | predicted - sensitive | FGFR Inhibitor (Pan) | Alpelisib + Infigratinib | Phase I | Actionable | In a Phase Ib trial, Truseltiq (infigratinib) and Alpelisib (BYL719) combination treatment resulted in partial response and a complete shrinkage of target lesions lasting 4 months in one urothelial carcinoma patient harboring a FGFR3-TACC3 fusion (J Clin Oncol 34, 2016 (suppl; abstr 2500)). | detail... |
| FGFR3 - TACC3 | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Balversa (erdafitinib) inhibited proliferation of transformed cells FGFR3-TACC3 in culture (PMID: 26992226). | 26992226 |
| FGFR3 - TACC3 | Advanced Solid Tumor | sensitive | FGFR3 Inhibitor | AZD4547 | Preclinical - Cell culture | Actionable | In a preclinical study, AZD4547 inhibited proliferation of transformed cells expressing FGFR3-TACC3 in culture (PMID: 26992226). | 26992226 |
| FGFR3 - TACC3 | bladder urothelial carcinoma | sensitive | FGFR Inhibitor (Pan) | PRN1371 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PRN1371 inhibited proliferation of bladder transitional cell carcinoma cell lines harboring FGFR3-TACC3 fusion in culture and tumor growth in cell line xenograft models (PMID: 28978721). | 28978721 |
| FGFR3 - TACC3 | oligodendroglioma | sensitive | FGFR Inhibitor (Pan) | PRN1371 | Preclinical - Pdx | Actionable | In a preclinical study, PRN1371 treatment resulted in tumor regression in patient-derived xenograft models of anaplastic oligodendroglioma harboring FGFR3-TACC3 fusion (PMID: 28978721). | 28978721 |
| FGFR3 - TACC3 | bladder transitional cell papilloma | no benefit | RO5126766 | Preclinical - Cell culture | Actionable | In a preclinical study, bladder transitional cell papilloma cells harboring FGFR3-TACC3 were not sensitive to RO5126766 in culture (PMID: 26438159). | 26438159 | |
| FGFR3 - TACC3 | bladder transitional cell papilloma | no benefit | RO4987655 | Preclinical - Cell culture | Actionable | In a preclinical study, bladder transitional cell papilloma cells harboring FGFR3-TACC3 were not sensitive to RO4987655 in culture (PMID: 26438159). | 26438159 | |
| FGFR3 - TACC3 | urinary bladder cancer | sensitive | FGFR3 Inhibitor | E7090 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, urinary bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability, and antitumor activity in xenograft models (PMID: 27535969). | 27535969 |
| FGFR3 - TACC3 | lung non-small cell carcinoma | sensitive | FGFR Inhibitor (Pan) | Erdafitinib | Preclinical - Pdx | Actionable | In a preclinical study, Balversa (erdafitinib) inhibited pERK signaling and tumor growth in a patient-derived xenograft (PDX) model of non-small cell lung cancer harboring FGFR3-TACC3 (PMID: 28341788). | 28341788 |
| FGFR3 - TACC3 | transitional cell carcinoma | sensitive | FGFR3 Inhibitor | AZD4547 + Buparlisib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) worked synergistically to induce apoptosis and inhibit growth of a urothelial cell carcinoma cell line harboring FGFR3-TACC3 in culture, and inhibited tumor growth in xenograft models, with increased efficacy over either agent alone (PMID: 28108151). | 28108151 |
| FGFR3 - TACC3 | urinary bladder cancer | sensitive | Derazantinib | Preclinical - Cell culture | Actionable | In a preclinical study, Derazantinib (ARQ 087) inhibited growth of bladder cancer cell lines harboring FGFR3-TACC3 fusion in culture (PMID: 27627808). | 27627808 | |
| FGFR3 - TACC3 | transitional cell carcinoma | predicted - sensitive | FGFR3 Inhibitor | AZD4547 | Case Reports/Case Series | Actionable | In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in a patient with urothelial carcinoma harboring FGFR3-TACC3, with a 70% reduction in target lesions and a progression-free survival of 10.9 months (PMID: 32463741; NCT02465060). | 32463741 |
| FGFR3 - TACC3 | cervical squamous cell carcinoma | predicted - sensitive | FGFR3 Inhibitor | AZD4547 | Case Reports/Case Series | Actionable | In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in a patient with squamous cell carcinoma of the cervix harboring FGFR3-TACC3, with a 40% reduction in target lesion size and a progression-free survival of 4 months (PMID: 32463741; NCT02465060). | 32463741 |
| FGFR3 - TACC3 | urinary bladder cancer | sensitive | FGFR Inhibitor (Pan) | ODM-203 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ODM-203 inhibited FGFR signaling and proliferation in a bladder cancer cell line harboring FGFR3-TACC3 and inhibited tumor growth in xenograft models (PMID: 30301864). | 30301864 |
| FGFR3 - TACC3 | transitional cell carcinoma | sensitive | FGFR Inhibitor (Pan) | Erdafitinib | FDA approved - On Companion Diagnostic | Actionable | In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3-TACC3 v1 and v3 fusions are included in the companion diagnostic (PMID: 31340094; NCT02365597). | detail... 31340094 detail... |
| FGFR3 - TACC3 | urinary bladder cancer | predicted - sensitive | FGFR Inhibitor (Pan) | Erdafitinib | Case Reports/Case Series | Actionable | In a Phase I trial, Balversa (erdafitinib) treatment resulted in a partial response with 38% shrinkage of tumor in a patient with metastatic bladder cancer harboring FGFR3-TACC3, who stayed on treatment for 10 months (PMID: 28416604; NCT01703481). | 28416604 |
| FGFR3 - TACC3 | gallbladder cancer | predicted - sensitive | FGFR3 Inhibitor | Debio 1347 | Case Reports/Case Series | Actionable | In a Phase I trial, Debio 1347 treatment resulted in stable disease in a patient with gallbladder cancer harboring FGFR3-TACC3 (PMID: 30745300; NCT01948297). | 30745300 |
| FGFR3 - TACC3 | transitional cell carcinoma | predicted - sensitive | FGFR3 Inhibitor | Debio 1347 | Case Reports/Case Series | Actionable | In a Phase I trial, Debio 1347 treatment resulted in partial response in two patients with urothelial cancer harboring FGFR3-TACC3 (PMID: 30745300; NCT01948297). | 30745300 |
| FGFR3 - TACC3 | bladder urothelial carcinoma | sensitive | FGFR Inhibitor (Pan) | Erdafitinib | FDA approved - On Companion Diagnostic | Actionable | In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3-TACC3 v1 and v3 fusions are included in the companion diagnostic (PMID: 31340094; NCT02365597). | detail... 31340094 detail... |
| FGFR3 - TACC3 | high grade glioma | sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical - Pdx | Actionable | In a preclinical study, Truseltiq (infigratinib) treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of glioma harboring FGFR3-TACC3 (Cancer Res 2019;79(13 Suppl):Abstract nr 2206). | detail... |
| FGFR3 - TACC3 | urinary bladder cancer | predicted - sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Truseltiq (infigratinib) treatment inhibited tumor growth and Erk phosphorylation in a cell line xenograft model of bladder cancer harboring FGFR3-TACC3 (Cancer Res 2019;79(13 Suppl):Abstract nr 2206). | detail... |
| FGFR3 - TACC3 | Advanced Solid Tumor | sensitive | FGFR3 Inhibitor | AZD4547 | Phase II | Actionable | In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in 22% (2/9) and stable disease in 55% (5/9) of patients with advanced solid tumors harboring FGFR fusions, with a 6-month progression-free survival rate of 56%, including partial responses in 2 patients and stable disease for greater than 6 months in 1 of 8 patients harboring FGFR3-TACC3 (PMID: 32463741; NCT02465060). | 32463741 |
| FGFR3 - TACC3 | urinary bladder cancer | sensitive | BO-264 | Preclinical - Cell culture | Actionable | In a preclinical study, BO-264 treatment inhibited Erk1/2 phosphorylation, induced mitotic arrest, and reduced viability of a urinary bladder cancer cell line harboring FGFR3-TACC3 in culture (PMID: 32217742). | 32217742 | |
| FGFR3 - TACC3 | urinary bladder cancer | sensitive | FGFR3 Inhibitor | PD173074 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PD173074 inhibited tumor growth in cell line xenograft models of bladder cancer harboring FGFR3-TACC3 (PMID: 23558953). | 23558953 |
| FGFR3 - TACC3 | Advanced Solid Tumor | predicted - sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR3-TACC3 were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
| FGFR3 - TACC3 | Advanced Solid Tumor | predicted - resistant | FGFR Inhibitor (Pan) | Dovitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR3-TACC3 were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467). | 34272467 |
| FGFR3 - TACC3 | central nervous system cancer | predicted - sensitive | FGFR3 Inhibitor | Debio 1347 | Case Reports/Case Series | Actionable | In a clinical case study, Debio 1347 treatment resulted in a prolonged stable disease and stable clinical symptoms at 26 months in a pediatric patient with a right cerebellar hemispheric rosette-forming glioneuronal tumor harboring an FGFR3-TACC3 fusion (PMID: 34250399). | 34250399 |
| FGFR3 - TACC3 | Advanced Solid Tumor | predicted - sensitive | HQP1351 | Preclinical - Cell culture | Actionable | In a preclinical study, GZD824 (HQP1351) inhibited growth of a cell line harboring FGFR3-TACC3 fusion in culture (PMID: 34114373). | 34114373 | |
| FGFR3 - TACC3 | high grade glioma | sensitive | FGFR Inhibitor (Pan) | Infigratinib | Case Reports/Case Series | Actionable | In a Phase II trial, Truseltiq (infigratinib) treatment resulted in limited efficacy with a 6-month progression-free survival (PFS) rate of 16.0%, a median PFS of 1.7 months, an objective response rate of 4.8% (1/21), and median overall survival of 6.7 months in patients with recurrent glioma harboring alterations in FGFR1 or FGFR3, however, resulted in stable disease with PFS of 30.2 months in a patient harboring FGFR3-TACC3 (PMID: 35344029; NCT01975701). | 35344029 |
| FGFR3 - TACC3 | stomach cancer | predicted - sensitive | FGFR Inhibitor (Pan) | Futibatinib | Case Reports/Case Series | Actionable | In a Phase I trial, Lytgobi (futibatinib) treatment led to an overall objective response rate of 22% (2/9, 2 partial responses) and a disease control rate of 55.6% (5/9) in patients with gastric cancer harboring an FGFR2 amplification or FGFR3 rearrangement, including a partial response with a progression-free survival of 6.7 months and a duration of response of 5.4 months in a gastric cancer patient harboring FGFR3-TACC3 (PMID: 34551969; NCT02052778). | 34551969 |
| FGFR3 - TACC3 | bladder urothelial carcinoma | sensitive | FGFR3 Inhibitor | Pemigatinib + Quisinostat | Preclinical - Patient cell culture | Actionable | In a preclinical study, Pemazyre (pemigatinib) and Quisinostat (JNJ-26481585) synergistically inhibited growth of a patient-derived bladder urothelial cancer cell line harboring FGFR3-TACC3 in culture (PMID: 36274097). | 36274097 |
| FGFR3 - TACC3 | Her2-receptor positive breast cancer | sensitive | FGFR Inhibitor (Pan) | Erdafitinib + Quisinostat | Preclinical - Cell culture | Actionable | In a preclinical study, Balversa (erdafitinib) and Quisinostat (JNJ-26481585) synergistically inhibited growth of a hormone receptor-negative, Erbb2 (Her2)-positive breast cancer cell line harboring FGFR3-TACC3 in culture (PMID: 36274097). | 36274097 |
| FGFR3 - TACC3 | urinary bladder cancer | predicted - sensitive | FGFR3 Inhibitor | TYRA-300 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, TYRA-300 induced tumor regression in a cell line xenograft model of bladder cancer harboring FGFR3-TACC3 (Annals of Oncology 33 (2022): S751). | detail... |
| FGFR3 - TACC3 | IDH-wildtype anaplastic astrocytoma | predicted - sensitive | FGFR Inhibitor (Pan) | Anlotinib + Temozolomide | Case Reports/Case Series | Actionable | In a clinical case study, Anlotinib (AL-3818) and Temodar (temozolomide) combination therapy resulted in a partial response that was maintained for at least 17 months from treatment initiation in a patient with recurrent IDH wild-type anaplastic astrocytoma harboring FGFR3-TACC3 (e17:e8) as well as FGFR3 amplification (CN=3.13) and TERT C228T (PMID: 32949176; NCT04004975). | 32949176 |